


PHARMACEUTICAL 2020

ADIAL PHARMACEUTICALS INC. Rank 319 of 362







PHARMACEUTICAL 2020

ADIAL PHARMACEUTICALS INC. Rank 319 of 362

The relative strengths and weaknesses of ADIAL PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ADIAL PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 142% points. The greatest weakness of ADIAL PHARMACEUTICALS INC. is the variable Net Income, reducing the Economic Capital Ratio by 429% points.

The company's Economic Capital Ratio, given in the ranking table, is -658%, being 355% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	7,673
Cost of Goods Sold	0
Intangible Assets	6.2
Liabilities, Current	539
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-347
Property and Equipment	0
Research and Development	3,966
Revenues	0
Selling, General and Administrative Expense	4,279

Output Variable	Value in 1000 USD
Assets	7,680
Liabilities	539
Expenses	8,245
Stockholders Equity	7,141
Net Income	-8,591
Comprehensive Net Income	-8,591
Economic Capital Ratio	-658%

